ESMO Open

Papers
(The H4-Index of ESMO Open is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors272
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches240
PP075 Xia Yuxue decoction inhibits hepatocellular carcinoma metastasis by reducing the abundance of the tumor-resident bacterium Brachybacterium sp.158
PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, strat154
PP002 Unravelling the effects of bisphenol A on colorectal cancer progression in obese Sprague-Dawley rats133
PP175 Unexpected high frequency of pathogenic germline variant (rs34804482, NM_018490.3: c.2531A>G) of the LGR4 gene in Tuvan ethnic group from West Siberia130
140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study120
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations113
130P Progesterone receptor (P) status and survival outcomes of ER-negative breast cancer: A population-based cohort study111
2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology109
137P PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts102
6P An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer99
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced94
Table of Contents94
97P Drug sensitivity prediction based on RNA expression profiling in colorectal cancer organoids91
Table of Contents89
Table of Contents88
ESMO85
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines81
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap78
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study74
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles73
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas72
76P Relative dose-intensity of trabectedin and outcome of advanced L-sarcomas71
143P Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: A cross-sectional study of published trials between 2015 and 202465
50P Combination of platinum-based chemotherapy with immunotherapy in treatment of extrapulmonary neuroendocrine carcinoma: A retrospective study65
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer64
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMAN62
58P Peripheral T cell phenotypes as predictors of progression and treatment response in mCRC: A prospective immunoprofiling study57
36P Next-generation sequencing in liquid biopsy for advanced NSCLC: Indian tertiary cancer centre experience56
Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards?56
8P Unveiling functional reprogramming in pancreatic cancer: An integrative transcriptomic and explainable machine learning approach56
Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes54
Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: developme53
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopaus53
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)52
22P PillPal.ai: Using artificial intelligence to improve adherence to oral chemotherapy, TKIs, and CDK4/6 Inhibitors - A pilot study from a tertiary cancer centre in India51
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer51
83P Efficacy and safety of KRAS G12C inhibitors across solid tumors: A systematic review and meta-analysis51
16eP Efficacy and safety of bevacizumab biosimilar in the treatment of brain metastases from breast cancer: A prospective, single-arm, multicentre, real-world study50
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single49
An innovative model of delivering cancer care in the community: the experience of a tertiary cancer centre in Singapore48
152P Pregnancy after gestational trophoblastic neoplasia: Navigating fertility post-chemotherapy48
Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced cancer patients48
43eP Is age a risk factor for locally advanced cervical cancer persistence?48
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial48
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]47
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets47
Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials47
0.20521903038025